Autolus Therapeutics plc (NASDAQ:AUTL) is among the 10 Best Penny Stocks to Buy for the Next 5 Years. Needham maintained a Buy rating on AUTL with a $10 price target, following the company’s positive second-quarter results, including $20.9 million in net product revenue from AUCATZYL.

The company is expanding its Activated Treatment Centers (ATCs), with 46 centers as of August 12, 2025, aiming for over 50 by year-end. Autolus Therapeutics plc (NASDAQ:AUTL) focuses on developing advanced T cell therapies for cancer and autoimmune diseases, showing promising growth potential in the biopharmaceutical sector.

While AUTL presents investment potential, certain AI stocks may offer better opportunities. For those seeking an undervalued AI stock benefiting from current economic trends, explore the best short-term AI stock. Discover more growth stocks to buy now and under-the-radar options for investment. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Needham Keeps Buy Rating on Autolus (AUTL) with a $10 Target